Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope

Christine Galustian; Angus Dalgleish; Mark Bodman-Smith; Sergei Kusmartsev; Prokar Dasgupta

doi:10.3389/fonc.2022.1021870

Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope

Christine Galustian, Angus Dalgleish, Mark Bodman-Smith, Sergei Kusmartsev, Prokar Dasgupta

Institute for Infection and Immunology, St. George's, University of London, London, United Kingdom.
Department of Urology, School of Medicine, University of Florida, Gainesville, FL, United States.

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	1021870
Journal	Frontiers in oncology
Volume	12
Early online date	8 Sept 2022
DOIs	https://doi.org/10.3389/fonc.2022.1021870
Publication status	E-pub ahead of print - 8 Sept 2022

Keywords

Provenge®
Prostate Cancer
Tumor microenvironment
Castration-resistant Prostate Cancer
Immunotherapy
CAR T cell therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2022.1021870Licence: CC BY

Cite this

@article{f602a8965ed5422baa3c4eee46737ae2,

title = "Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope",

keywords = "Provenge{\textregistered}, Prostate Cancer, Tumor microenvironment, Castration-resistant Prostate Cancer, Immunotherapy, CAR T cell therapy",

author = "Christine Galustian and Angus Dalgleish and Mark Bodman-Smith and Sergei Kusmartsev and Prokar Dasgupta",

year = "2022",

month = sep,

day = "8",

doi = "10.3389/fonc.2022.1021870",

language = "English",

volume = "12",

pages = "1021870",

journal = "Frontiers in oncology",

issn = "2234-943X",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope

AU - Galustian, Christine

AU - Dalgleish, Angus

AU - Bodman-Smith, Mark

AU - Kusmartsev, Sergei

AU - Dasgupta, Prokar

PY - 2022/9/8

Y1 - 2022/9/8

KW - Provenge®

KW - Prostate Cancer

KW - Tumor microenvironment

KW - Castration-resistant Prostate Cancer

KW - Immunotherapy

KW - CAR T cell therapy

U2 - 10.3389/fonc.2022.1021870

DO - 10.3389/fonc.2022.1021870

M3 - Editorial

C2 - 36158670

SN - 2234-943X

VL - 12

SP - 1021870

JO - Frontiers in oncology

JF - Frontiers in oncology

ER -